Edna “Eti” Cukierman, co-director of the Marvin & Concetta Greenberg Pancreatic Cancer Institute and co-leader of the Cancer Signaling and Microenvironment Research Program at Fox Chase Cancer Center, was recently awarded the American Cancer Society’s Wilmott Family Professorship in Pancreatic Cancer.
In a phase II clinical trial, a research team led by Nilofer Azad, professor of oncology and co-leader of the Kimmel Cancer Center’s Cancer Genetics and Epigenetics Program, and Marina Baretti, the Jiasheng Chair in Hepato-Biliary Cancer at the Kimmel Cancer Center, tested the safety and efficacy of the combination of two drugs: an immunotherapy, nivolumab, and an epigenetic drug, entinostat—a histone deacetylase inhibitor.
